FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595267236> ?p ?o ?g. }

• W2595267236 endingPage "69" @default.
• W2595267236 startingPage "61" @default.
• W2595267236 abstract "Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) are responsible for increases in antimicrobial-resistant infections worldwide. We determined in vitro susceptibilities to eight parenteral antimicrobial agents using Clinical and Laboratory Standards Institute broth microdilution methodology for Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal infections (IAIs) (n=3052) and urinary tract infections (UTIs) (n=1088) in 11 Asia-Pacific countries/regions from 2013 to 2015. Amikacin (98.3, 96.4 %), imipenem (97.1, 95.5 %) and ertapenem (95.3, 93.2 %) demonstrated the highest rates of susceptibility for isolates of K. pneumoniae from IAI and UTI, respectively, whereas susceptibility to advanced-generation cephalosporins was <84 and <71 %, respectively. K. pneumoniae with an extended-spectrum β-lactamase-positive phenotype were more common in UTI (27.1 %) than IAI (16.2 %). Imipenem and amikacin were the most active agents against extended-spectrum β-lactamase-positive K. pneumoniae from IAI (95.1, 91.8 %) and UTI (94.9, 92.3 %), respectively, whereas <54 % were susceptible to piperacillin-tazobactam. Against Enterobacter spp. and P. aeruginosa, amikacin demonstrated the highest rates of susceptibility for isolates from IAI (99.7, 95.5 %) and UTI (90.9, 91.5 %), respectively. K. pneumoniae, Enterobacter spp. and P. aeruginosa from urine demonstrated lower susceptibility to levofloxacin (74.1, 81.8 and 73.8 %) than from IAI (87.6, 91.8 and 85.4 %). For A. baumannii, rates of susceptibility to all agents tested were <43 %. We conclude that the studied Gram-negative ESKAPE pathogens demonstrated reduced susceptibility to commonly prescribed advanced-generation cephalosporins, piperacillin-tazobactam and levofloxacin, while amikacin and carbapenems were the most active. Ongoing surveillance to monitor evolving resistance trends and the development of novel antimicrobial agents with potent activity against Gram-negative ESKAPE pathogens are mandatory." @default.
• W2595267236 created "2017-03-23" @default.
• W2595267236 creator A5017159626 @default.
• W2595267236 creator A5033454548 @default.
• W2595267236 creator A5038009031 @default.
• W2595267236 creator A5061522332 @default.
• W2595267236 creator A5062847775 @default.
• W2595267236 date "2017-01-01" @default.
• W2595267236 modified "2023-10-18" @default.
• W2595267236 title "Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia–Pacific countries: SMART 2013–2015" @default.
• W2595267236 cites W1618166169 @default.
• W2595267236 cites W1986165865 @default.
• W2595267236 cites W1991566300 @default.
• W2595267236 cites W2005600183 @default.
• W2595267236 cites W2034026426 @default.
• W2595267236 cites W2043982549 @default.
• W2595267236 cites W2055329510 @default.
• W2595267236 cites W2059728033 @default.
• W2595267236 cites W2076016627 @default.
• W2595267236 cites W2104256777 @default.
• W2595267236 cites W2110519991 @default.
• W2595267236 cites W2115486016 @default.
• W2595267236 cites W2121227144 @default.
• W2595267236 cites W2145541037 @default.
• W2595267236 cites W2149186506 @default.
• W2595267236 cites W2168519960 @default.
• W2595267236 cites W2201379139 @default.
• W2595267236 cites W2276725448 @default.
• W2595267236 cites W2288514582 @default.
• W2595267236 doi "https://doi.org/10.1099/jmm.0.000421" @default.
• W2595267236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28051952" @default.
• W2595267236 hasPublicationYear "2017" @default.
• W2595267236 type Work @default.
• W2595267236 sameAs 2595267236 @default.
• W2595267236 citedByCount "53" @default.
• W2595267236 countsByYear W25952672362017 @default.
• W2595267236 countsByYear W25952672362018 @default.
• W2595267236 countsByYear W25952672362019 @default.
• W2595267236 countsByYear W25952672362020 @default.
• W2595267236 countsByYear W25952672362021 @default.
• W2595267236 countsByYear W25952672362022 @default.
• W2595267236 countsByYear W25952672362023 @default.
• W2595267236 crossrefType "journal-article" @default.
• W2595267236 hasAuthorship W2595267236A5017159626 @default.
• W2595267236 hasAuthorship W2595267236A5033454548 @default.
• W2595267236 hasAuthorship W2595267236A5038009031 @default.
• W2595267236 hasAuthorship W2595267236A5061522332 @default.
• W2595267236 hasAuthorship W2595267236A5062847775 @default.
• W2595267236 hasBestOaLocation W25952672361 @default.
• W2595267236 hasConcept C104317684 @default.
• W2595267236 hasConcept C176947019 @default.
• W2595267236 hasConcept C2776315533 @default.
• W2595267236 hasConcept C2776685102 @default.
• W2595267236 hasConcept C2777058267 @default.
• W2595267236 hasConcept C2777427914 @default.
• W2595267236 hasConcept C2777637488 @default.
• W2595267236 hasConcept C2778523567 @default.
• W2595267236 hasConcept C2778983983 @default.
• W2595267236 hasConcept C2779631663 @default.
• W2595267236 hasConcept C2780950330 @default.
• W2595267236 hasConcept C4937899 @default.
• W2595267236 hasConcept C501593827 @default.
• W2595267236 hasConcept C523546767 @default.
• W2595267236 hasConcept C54355233 @default.
• W2595267236 hasConcept C547475151 @default.
• W2595267236 hasConcept C55493867 @default.
• W2595267236 hasConcept C71924100 @default.
• W2595267236 hasConcept C86803240 @default.
• W2595267236 hasConcept C89423630 @default.
• W2595267236 hasConcept C94665300 @default.
• W2595267236 hasConceptScore W2595267236C104317684 @default.
• W2595267236 hasConceptScore W2595267236C176947019 @default.
• W2595267236 hasConceptScore W2595267236C2776315533 @default.
• W2595267236 hasConceptScore W2595267236C2776685102 @default.
• W2595267236 hasConceptScore W2595267236C2777058267 @default.
• W2595267236 hasConceptScore W2595267236C2777427914 @default.
• W2595267236 hasConceptScore W2595267236C2777637488 @default.
• W2595267236 hasConceptScore W2595267236C2778523567 @default.
• W2595267236 hasConceptScore W2595267236C2778983983 @default.
• W2595267236 hasConceptScore W2595267236C2779631663 @default.
• W2595267236 hasConceptScore W2595267236C2780950330 @default.
• W2595267236 hasConceptScore W2595267236C4937899 @default.
• W2595267236 hasConceptScore W2595267236C501593827 @default.
• W2595267236 hasConceptScore W2595267236C523546767 @default.
• W2595267236 hasConceptScore W2595267236C54355233 @default.
• W2595267236 hasConceptScore W2595267236C547475151 @default.
• W2595267236 hasConceptScore W2595267236C55493867 @default.
• W2595267236 hasConceptScore W2595267236C71924100 @default.
• W2595267236 hasConceptScore W2595267236C86803240 @default.
• W2595267236 hasConceptScore W2595267236C89423630 @default.
• W2595267236 hasConceptScore W2595267236C94665300 @default.
• W2595267236 hasIssue "1" @default.
• W2595267236 hasLocation W25952672361 @default.
• W2595267236 hasLocation W25952672362 @default.
• W2595267236 hasOpenAccess W2595267236 @default.
• W2595267236 hasPrimaryLocation W25952672361 @default.
• W2595267236 hasRelatedWork W1481826480 @default.
• W2595267236 hasRelatedWork W1788363151 @default.

• next